Document:

onfolio_ex103.htm

EXHIBIT 10.3
  
 Amendment No. 1
 to
 Onfolio Holdings Inc. 2020 Equity Incentive Plan
  
 On August 11, 2022, Onfolio Holdings Inc. effectuated a 1-for-4.7619 reverse split of its common stock, so that each 4.7619 shares of common stock issued and outstanding immediately prior to August 11, 2022 was combined and converted into one (1) share of common stock. As a result of the reverse split, the Onfolio Holdings Inc. 2020 Equity Incentive Plan (the “Plan”) is hereby amended as follows (capitalized terms used herein and not defined herein shall have the respective meaning ascribed to such terms in the Plan):
  
  
 	  
	 1.
	 Section 4.1 of the Plan shall be deleted in its entirety and replaced with the following:

 
 
  
  
 	  
	 4.1
	 Subject to adjustment in accordance with Section 11, no more than 2,600,000 shares of Common Stock shall be available for the grant of Awards under the Plan (the "Total Share Reserve"); however, at the time of any grant of Awards under the Plan, no more than the lesser of (i) the Total Share Reserve, or (ii) the number of shares of Common Stock equal to 20% of the total shares of Common Stock outstanding at the time of any such grant of Awards under the Plan, shall be available for the grant of Awards under the Plan. During the terms of the Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Awards.

 
 
  
  
 	  
	 2.
	 Section 4.3 of the Plan shall be deleted in its entirety and replaced with the following:

 
 
  
  
 	  
	 4.3
	 Subject to adjustment in accordance with Section 11, the maximum number of shares of Common Stock that may be issued in the aggregate pursuant to the exercise of Incentive Stock Options is equal to the number of shares of Common Stock available for the grant of Awards under the Plan (the "ISO Limit").

 
 
  
  
 	  
	 3.
	 All other provisions of the Plan remain in full force and effect, other than any provision that conflicts with the terms and spirit of this amendment.

 
 
  
 Adopted by the Board of Directors on August 15, 2022.
  
 Adopted by the stockholders on August 15, 2022.EX-10.1

   

   

  Exhibit 10.1

   

  [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

   

  Amendment to the Asset Purchase Agreement

   

  This Amendment to the Asset Purchase Agreement (the “Amendment”) is made and entered into as of May 23, 2022 (the “Amendment Effective Date”), between Millennium Pharmaceuticals, Inc., a Delaware corporation (“Seller”), and Calithera Biosciences, Inc., a Delaware corporation (“Buyer”).  Seller and Buyer are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

   

  Recitals

  A.	Buyer and Seller are parties to an Asset Purchase Agreement, dated October 18, 2021 (the “Agreement”).

   

  B.	The Parties wish to amend certain terms of the Agreement in accordance with Section 10.1 thereof.

  Now, Therefore, in consideration of the premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, Buyer and Seller hereby agree as follows:

  1.Amendment of the Agreement

  The Parties hereby agree to amend the terms of the Agreement as provided below, effective as of the Amendment Effective Date.  Where the Agreement is not explicitly amended, the terms of the Agreement will remain in force.  Capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings such terms are given in the Agreement.  This Amendment and all discussions pertaining hereto are subject to Article 7 of the Agreement.

  1.1Section 9.4.1 is hereby deleted in its entirety and replaced with the following:

  9.4.1	Deductible.  

  (a)	Subject to Section 9.4.4, no Claim may be made by Seller as the Indemnified Party for indemnification pursuant to Section 9.2 for breach of any representation or warranty in Section 6.2 until the aggregate amount of Losses for which a Seller Indemnified Party seeks to be indemnified pursuant to Section 9.2 exceeds $[***] (Seller’s “Deductible”), at which time the Seller Indemnified Parties shall be entitled to indemnification for all such Losses in excess of Seller’s Deductible.  

  (b)	Subject to Section 9.4.4, no Claim may be made by Buyer as the Indemnified Party for indemnification pursuant to Section 9.3 for breach of any representation or warranty in Section 6.1 until the aggregate amount of Losses for which a Buyer Indemnified Party seeks to be indemnified pursuant to Section 9.3 exceeds $[***] 

   

   

  

   

  (Buyer’s “Deductible”), at which time the Buyer Indemnified Parties shall be entitled to indemnification for all such Losses in excess of the Buyer’s Deductible.

  1.2Schedule 1.1(c) (Materials) is hereby amended to [***].  In addition, the following proviso will be deemed to be added to the sentence at the top of Schedule 1.1(c):  [***]

  2.Miscellaneous

  1.1Full Force and Effect.  This Amendment amends the terms of the Agreement and is deemed incorporated into the Agreement.  The provisions of the Agreement, as amended by this Amendment, remain in full force and effect.  

  1.2Entire Agreement.  The Agreement and this Amendment constitute the entire agreement between the Parties as to the subject matter of this Amendment.

  1.3Counterparts. This Amendment may be executed in counterparts by a single Party, each of which when taken together shall constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including .pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

  1.4Governing Law; Jurisdiction.  This Amendment and its effect are subject to and shall be construed and enforced in accordance with the law of the State of New York, without regard to its conflicts of laws that would require the application of any other Law. Each of the Parties hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the federal courts located in the Southern District of the State of New York for any matter arising out of or relating to this Amendment and the transactions contemplated hereby, and agrees not to commence any litigation relating thereto except in such courts. Each of the Parties hereby irrevocably and unconditionally waives any objection to the laying of venue of any matter arising out of this Amendment or the transactions contemplated hereby in the courts of the State of New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such matter brought in any such court has been brought in an inconvenient forum. The Parties agree that a final judgment in any such matter shall be conclusive and may be enforced in other jurisdictions by suits on the judgment or in any other manner provided by law. Any proceeding brought by either Party under this Amendment shall be exclusively conducted in the English language.

  1.5Waiver of Jury Trial.  To the fullest extent permitted by Law, each of the Parties irrevocably waives all right to trial by jury in any Litigation arising out of or relating to this Amendment or any of the transactions contemplated by this Amendment.

  1.6Compliance with Law; Severability.  Nothing in this Amendment shall be construed to require the commission of any act contrary to Law. If any one or more provisions of this Amendment is held to be invalid, illegal or unenforceable, the affected provisions of this Amendment shall be curtailed and limited only to the extent necessary to bring it within the applicable legal requirements and the validity, legality and enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby.

  2

   

   

  

   

  1.7Waivers.  A Party’s consent to or waiver, express or implied, of the other Party’s breach of its obligations hereunder shall not be deemed to be or construed as a consent to or waiver of any other breach of the same or any other obligations of such breaching Party. A Party’s failure to complain of any act, or failure to act, by the other Party, to declare the other Party in default, to insist upon the strict performance of any obligation or condition of this Amendment or to exercise any right or remedy consequent upon a breach thereof, no matter how long such failure continues, shall not constitute a waiver by such Party of its rights hereunder, of any such breach, or of any other obligation or condition. A Party’s consent in any one instance shall not limit or waive the necessity to obtain such Party’s consent in any future instance and in any event no consent or waiver shall be effective for any purpose hereunder unless such consent or waiver is in writing and signed by the Party granting such consent or waiver.

  1.8Headings.  Article and Section headings used herein are for convenient reference only, and are not a part of this Amendment. 

  1.9Further Assurances.  From time to time after the Amendment Effective Date, and for no further consideration (except as expressly set forth in Agreement as amended by this Amendment), each Party shall execute, acknowledge and deliver such assignments, transfers, consents, assumptions and other documents and instruments and take such other actions as may be necessary or desirable to consummate and make effective the transactions contemplated by this Amendment.

  1.10Representations and Warranties of the Parties.  Each Party (as such, the “Representing Party”) represents and warrants to the other Party that:

  (a)Organization and Standing.  The Representing Party is a corporation duly organized, validly existing and in good standing under the laws of Delaware.

  (b)Binding Agreement.  This Amendment has been duly and validly executed and delivered on behalf of the Representing Party and, assuming the due authorization, execution and delivery by the other Party, constitutes the legal and binding obligation of the Representing Party enforceable against the Representing Party in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally and to general equity principles (whether considered in a proceeding in equity or at law).

  (c)Authorization.  The Representing Party has all requisite power and authority to execute this Amendment, to carry out and perform its obligations under this Amendment and the Agreement as amended by this Amendment and to consummate the transactions contemplated hereunder and thereunder.  The execution, delivery and performance by the Representing Party of this Amendment, and the consummation of the transactions contemplated hereunder, have been duly and validly authorized by all necessary action of the Representing Party.

  (d)Consents; No Violation, Etc.  The execution and delivery of this Amendment does not, and the consummation of the transactions contemplated hereby will not (i) violate any Law applicable to the Representing Party or its Affiliates, (ii) conflict with any provision of the certificate of incorporation, bylaws or other organizational documents of the Representing Party, (iii) give rise to any approval, authorization, consent, license, filing or registration with any Court or Governmental Entity or (iv) violate any material Contract of the Representing Party, or to which 

  3

   

   

  

   

  the Representing Party is a party or subject to or by which it or any of its assets or properties is otherwise bound; provided, however, that no representation or warranty is made in the foregoing clause (i) or (iv) with respect to matters that, individually or in the aggregate, would not, in the case of Seller as the Representing Party, result in a material adverse effect on the Acquired Assets or the transactions contemplated by this Amendment or the Agreement, or in the case of Buyer as the Representing Party, materially interfere with Buyer’s performance of its obligations under this Amendment or the Agreement as amended by this Amendment.

   

   

  4

   

   

  

   

   

  In Witness Whereof, this Amendment has been executed by the Parties hereto all as of the date first above written.

   

  		
	Millennium Pharmaceuticals, Inc.
	Calithera Biosciences, Inc.
 

	By: /s/ Michael Martin                        
 
Name:  Michael Martin
 
Title:    Authorized Signatory
	By: /s/  Susan M. Molineaux, Ph.D.
 
Name: Susan M. Molineaux, Ph.D.
 
Title:   President and Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]